Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis

CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, future systematic reviews should also include non-randomized studies.PMID:38032059 | PMC:PMC10687854 | DOI:10.1002/14651858.CD012186.pub2

Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research